atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
pharma · Steroid refractory Acute Graft versus host Disease · moderate to severe atopic dermatitis
Medac Gesellschaft fuer
Medac Gesellschaft fuer klinische Spezialpraeparate mbH
Medac Gesellschaft fuer drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 3
- Drugs
- 14
- Patents
- 0
Medac Gesellschaft fuer pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Medac Gesellschaft fuer drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Medac Gesellschaft fuer in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
everolimus
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
Development asset linked to Medac Gesellschaft fuer in public FDA and regional records.
-
folic acid
Various (V04)US regulatory status: approved.
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Medac Gesellschaft fuer in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Medac Gesellschaft fuer in public FDA and regional records.
-
tacrolimus
Dermatologicals (D11)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
Development asset linked to Medac Gesellschaft fuer in public FDA and regional records.
-
Development asset linked to Medac Gesellschaft fuer in public FDA and regional records.
-
treosulfan
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA cross-linking agent